Broadridge Financial Solutions Free cash flow decreased by 9.7% to $287.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 17.6%, from $348.90M to $287.50M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 24.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q4 '21 | Q1 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $440.20M | -$141.10M | $450.30M | -$210.00M | $112.70M | $170.00M | $712.20M | -$66.70M | $177.70M | $184.60M | $703.20M | -$133.40M | $227.90M | $348.90M | $684.10M | $27.10M | $318.50M | $287.50M |
| QoQ Change | — | -132.1% | +419.1% | -146.6% | +153.7% | +50.8% | +318.9% | -109.4% | +366.4% | +3.9% | +280.9% | -119.0% | +270.8% | +53.1% | +96.1% | -96.0% | >999% | -9.7% |
| YoY Change | — | — | +2.3% | -48.8% | — | — | +58.2% | +68.2% | +57.7% | +8.6% | -1.3% | -100.0% | +28.2% | +89.0% | -2.7% | +120.3% | +39.8% | -17.6% |